Prospects of NSAIDs administration as double-edged agents against endometrial cancer and pathological species of the uterine microbiome.Many types of cancers, including endometrial cancer, were found to have cyclooxygenase-2 (COX-2) overexpression.  Because this enzyme belongs to the group of pro-inflammatory enzymes, so-called NSAIDs (non-steroidal anti-inflammatory drugs) directly inhibit its activity.  Besides, NSAIDs can affect some bacteria, which are vaginal/endometrial microbiome members.  The purpose of this review is to highlight the COX-2 enzyme role in endometrial cancer, the potential effect of the endometrial microbiome on COX-2 enzyme overexpression, and the prospects of NSAIDs use in terms of this type of cancer.
NSAIDs
Prospects of NSAIDs administration as double-edged agents against endometrial cancer and pathological species of the uterine microbiome.Many types of cancers, including endometrial cancer, were found to have cyclooxygenase-2 (COX-2) overexpression.  An increasing number of reports on COX-2 involvement in cancer, as well as on the role of microbiota in abnormal metabolism and signaling of cells, forces the development of new NSAID types.  The purpose of this review is to highlight the COX-2 enzyme role in endometrial cancer, the potential effect of the endometrial microbiome on COX-2 enzyme overexpression, and the prospects of NSAIDs use in terms of this type of cancer.
COX-2
Prospects of NSAIDs administration as double-edged agents against endometrial cancer and pathological species of the uterine microbiome.Many types of cancers, including endometrial cancer, were found to have cyclooxygenase-2 (COX-2) overexpression.  Because this enzyme belongs to the group of pro-inflammatory enzymes, so-called NSAIDs (non-steroidal anti-inflammatory drugs) directly inhibit its activity.  Besides, NSAIDs can affect some bacteria, which are vaginal/endometrial microbiome members.  The purpose of this review is to highlight the COX-2 enzyme role in endometrial cancer, the potential effect of the endometrial microbiome on COX-2 enzyme overexpression, and the prospects of NSAIDs use in terms of this type of cancer.
NSAIDs